A German multicenter real‐world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma

Abstract Bispecific T‐cell engagers (BTCEs) represent a paradigm shift in the treatment of relapsed/refractory multiple myeloma (RRMM). Talquetamab, a GPRC5DxCD3 BTCE, has shown promising results in the MonumenTAL‐1 trial and was recently approved by the Food and Drug Administration and the European...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Jan H. Frenking, Christine Riedhammer, Raphael Teipel, Florian Bassermann, Britta Besemer, Moritz Bewarder, Jan Braune, Annamaria Brioli, Franziska Brunner, Maria Dampmann, Roland Fenk, Deniz N. Gezer, Sarah Goldman‐Mazur, Christine Hanoun, Marion Högner, Cyrus Khandanpour, Katja Kolditz, Igor Kos, Jan Krönke, Miriam Kull, Valentine Landrin, Theo Leitner, Maximilian Merz, Ivana vonMetzler, Christian S. Michel, Carsten Müller‐Tidow, Sebastian Theurich, Karolin Trautmann‐Grill, Ralph Wäsch, Romans Zukovs, Mathias Hänel, Leo Rasche, Marc S. Raab
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Wiley 2025-04-01
سلاسل:	HemaSphere
الوصول للمادة أونلاين:	https://doi.org/10.1002/hem3.70114
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!